Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Feb;84(4):571–578. doi: 10.1054/bjoc.2000.1633

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin

D J Flavell 1, D A Boehm 1, A Noss 1, S L Warnes 1, S U Flavell 1
PMCID: PMC2363766  PMID: 11207056

Abstract

Severe combined immunodeficient (SCID) mice injected i.v. with the human T-ALL cell line CCRF CEM (SCID-CEM mice) develop within 50 days life-threatening multi-organ growth of leukaemia cells. The development of leukaemia in SCID-CEM mice treated with three 10 μg i.v. doses of the anti-CD7 immunotoxin (IT) HB2-SAPORIN or the anti-CD38 IT OKT10-SAPORIN was significantly delayed compared with PBS sham-treated animals but 90% of animals treated with either IT eventually developed disseminated leukaemia cell growth. In contrast treatment of SCID-CEM mice with a combination of both ITs led not only to a significantly greater delay in time to leukaemia development but also in the numbers of animals remaining leukaemia free (60%). The native HB2 and OKT10 antibodies (both murine IgG 1 antibodies) exerted significant, though relatively weak therapeutic effects, probably mediated through an antibody-dependent cellular cytotoxicity (ADCC) mechanism. Moreover, there was no in vivo additivity of therapeutic effect when both antibodies were used in combination. Apparent, however, was that the combination of HB2-SAPORIN IT with OKT10 antibody led to an intermediate therapeutic effect that was significantly greater than that obtained when either was used alone but significantly less than that obtained when the two IT combination was utilized. This was similarly the case for the combination of OKT10-SAPORIN IT with HB2 antibody though the effect was less pronounced in this instance. This result suggests that the therapeutic effect of IT + antibody treatment results from an additivity between antibody-mediated delivery of saporin combined with a SCID mouse NK cell-mediated ADCC attack on the target cell directed through target cell bound antibody Fc engagement with FcγRIII on the NK cell surface. The combination of both ITs however gave the best therapeutic outcome in SCID-CEM mice probably as the result of (i) delivery of greater amounts of saporin to target CEM cells positive for both CD7 and CD38, (ii) delivery of an effective dose of saporin to CEM cells downregulated or negative for one of the target antigens and (iii) through ADCC mechanisms that interact additively with IT action. We have previously proposed that combination IT therapy would be one means of overcoming the problem of heterogeneity of antigen expression within a global tumour cell population and these additional findings support this and provide a further strengthening of the rationale for employing cocktails of ITs for the treatment of human malignancies. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: T-cell leukaemia, combination immunotoxin therapy, SCID mouse

Full Text

The Full Text of this article is available as a PDF (152.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergamaschi G., Perfetti V., Tonon L., Novella A., Lucotti C., Danova M., Glennie M. J., Merlini G., Cazzola M. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. Br J Haematol. 1996 Jun;93(4):789–794. doi: 10.1046/j.1365-2141.1996.d01-1730.x. [DOI] [PubMed] [Google Scholar]
  2. Bosma G. C., Custer R. P., Bosma M. J. A severe combined immunodeficiency mutation in the mouse. Nature. 1983 Feb 10;301(5900):527–530. doi: 10.1038/301527a0. [DOI] [PubMed] [Google Scholar]
  3. Endo Y., Tsurugi K., Lambert J. M. The site of action of six different ribosome-inactivating proteins from plants on eukaryotic ribosomes: the RNA N-glycosidase activity of the proteins. Biochem Biophys Res Commun. 1988 Feb 15;150(3):1032–1036. doi: 10.1016/0006-291x(88)90733-4. [DOI] [PubMed] [Google Scholar]
  4. FOLEY G. E., LAZARUS H., FARBER S., UZMAN B. G., BOONE B. A., MCCARTHY R. E. CONTINUOUS CULTURE OF HUMAN LYMPHOBLASTS FROM PERIPHERAL BLOOD OF A CHILD WITH ACUTE LEUKEMIA. Cancer. 1965 Apr;18:522–529. doi: 10.1002/1097-0142(196504)18:4<522::aid-cncr2820180418>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  5. Flavell D. J., Boehm D. A., Emery L., Noss A., Ramsay A., Flavell S. U. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone. Int J Cancer. 1995 Jul 28;62(3):337–344. doi: 10.1002/ijc.2910620318. [DOI] [PubMed] [Google Scholar]
  6. Flavell D. J., Noss A., Pulford K. A., Ling N., Flavell S. U. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice. Cancer Res. 1997 Nov 1;57(21):4824–4829. [PubMed] [Google Scholar]
  7. Flavell D. J. Saporin immunotoxins. Curr Top Microbiol Immunol. 1998;234:57–61. doi: 10.1007/978-3-642-72153-3_4. [DOI] [PubMed] [Google Scholar]
  8. Flavell D. J., Warnes S., Noss A., Flavell S. U. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia. Cancer Res. 1998 Dec 15;58(24):5787–5794. [PubMed] [Google Scholar]
  9. Frankel A. E., Kreitman R. J., Sausville E. A. Targeted toxins. Clin Cancer Res. 2000 Feb;6(2):326–334. [PubMed] [Google Scholar]
  10. Ghetie M. A., Picker L. J., Richardson J. A., Tucker K., Uhr J. W., Vitetta E. S. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. Blood. 1994 Mar 1;83(5):1329–1336. [PubMed] [Google Scholar]
  11. Ghetie M. A., Tucker K., Richardson J., Uhr J. W., Vitetta E. S. The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood. 1992 Nov 1;80(9):2315–2320. [PubMed] [Google Scholar]
  12. Glennie M. J., McBride H. M., Stirpe F., Thorpe P. E., Worth A. T., Stevenson G. T. Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin. J Exp Med. 1987 Jul 1;166(1):43–62. doi: 10.1084/jem.166.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kreitman R. J. Immunotoxins in cancer therapy. Curr Opin Immunol. 1999 Oct;11(5):570–578. doi: 10.1016/s0952-7915(99)00005-9. [DOI] [PubMed] [Google Scholar]
  14. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  15. Lambert J. M., Senter P. D., Yau-Young A., Blättler W. A., Goldmacher V. S. Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins. J Biol Chem. 1985 Oct 5;260(22):12035–12041. [PubMed] [Google Scholar]
  16. Morland B. J., Barley J., Boehm D., Flavell S. U., Ghaleb N., Kohler J. A., Okayama K., Wilkins B., Flavell D. J. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice. Br J Cancer. 1994 Feb;69(2):279–285. doi: 10.1038/bjc.1994.52. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Stirpe F., Gasperi-Campani A., Barbieri L., Falasca A., Abbondanza A., Stevens W. A. Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree). Biochem J. 1983 Dec 15;216(3):617–625. doi: 10.1042/bj2160617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Stong R. C., Uckun F., Youle R. J., Kersey J. H., Vallera D. A. Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood. 1985 Sep;66(3):627–635. [PubMed] [Google Scholar]
  19. Stross W. P., Warnke R. A., Flavell D. J., Flavell S. U., Simmons D., Gatter K. C., Mason D. Y. Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen. J Clin Pathol. 1989 Sep;42(9):953–961. doi: 10.1136/jcp.42.9.953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Thorpe P. E., Brown A. N., Bremner J. A., Jr, Foxwell B. M., Stirpe F. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. J Natl Cancer Inst. 1985 Jul;75(1):151–159. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES